# Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

> **NCT07046221** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Esophagus Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Albumin-Bound Paclitaxel
- **DRUG:** cis-platinum
- **PROCEDURE:** Surgery
- **RADIATION:** Radiation
- **DRUG:** Nedaplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT07046221
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2027-08-01
- **Final completion:** 2030-08-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07046221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07046221, "Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07046221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*